Program
catequentinib hydrochloride
Also written as “Anlotinib Hydrochloride Capsules”, “Anlotinib hydrochloride capsule” and “Anlotinib Hydrochloride Capsule”.
Its studies are mostly in Endometrial Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Sarcoma, Alveolar Soft Part, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 207 open or running | phase 4since Apr 14, 2023 | Apr 10, 2020 | Dec 2026phase 3 · NCT04344158 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Apr 10, 2020.
- Jul 13, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04964479 · 375 enrolled · China
- Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerNCT05068206 · 120 enrolled · China
- Nov 15, 2021Phase 2 study in Endometrial NeoplasmsNCT05121363 · 113 enrolled · China
- Nov 23, 2021Phase 3 study in Recurrent Platinum-resistant Ovarian CancerNCT05145218 · 405 enrolled · China
- Jul 6, 2022Phase 2 study in Advanced Endometrial CancerNCT05481645 · 71 enrolled · China
- Sep 27, 2022Phase 1 study in Liver DiseasesNCT05559242 · 30 enrolled · China
- Apr 14, 2023Phase 4 study in Carcinoma, MedullaryNCT05830500 · 360 planned · China
- May 15, 2023Phase 3 study in Carcinoma, HepatocellularNCT05862337 · 480 planned · China
- Jun 13, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05913089 · 58 planned · China
- Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaNCT05975645 · 29 enrolled · China
- Jun 21, 2024Phase 3 study in Endometrial NeoplasmsNCT06475599 · 420 planned · China
- Mar 19, 2025Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06897579 · 40 enrolled · China
- Apr 17, 2026Phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177 · 33 planned · China
- Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177
Ahead
- Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04344158
- Jun 2027Primary completion: phase 4 study in Carcinoma, MedullaryNCT05830500
- Dec 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT06475599
- Dec 2028Primary completion: phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07548177Sarcoma, Alveolar Soft Part · China | 2 | Recruiting | Dec 2028 | 33 |
| NCT06897579Extensive Stage Small Cell Lung Cancer · China | 2 | Terminated | Apr 15, 2026 | 40 |
| NCT06475599Endometrial Neoplasms · China | 3 | Not yet recruiting | Dec 2027 | 420 |
| NCT05975645Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Jun 4, 2025 | 29 |
| NCT05913089Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2026 | 58 |
| NCT05862337Carcinoma, Hepatocellular · China | 3 | Recruiting | Aug 2024 | 480 |
| NCT05830500Carcinoma, Medullary · China | 4 | Recruiting | Jun 2027 | 360 |
| NCT05559242Liver Diseases · China | 1 | UNKNOWN | Jun 2023 | 30 |
| NCT05481645Advanced Endometrial Cancer · China | 2 | Terminated | Feb 1, 2024 | 71 |
| NCT05145218Recurrent Platinum-resistant Ovarian Cancer · China | 3 | UNKNOWN | Oct 2024 | 405 |
| NCT05121363Endometrial Neoplasms · China | 2 | UNKNOWN | May 2023 | 113 |
| NCT05068206Unresectable Metastatic Colorectal Cancer · China | 2 | UNKNOWN | Dec 2023 | 120 |
| NCT04964479Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Dec 2022 | 375 |
| NCT04924192Advanced Lung Carcinoma · China | 2 | Terminated | Sep 27, 2022 | 21 |
| NCT04854668Colorectal Neoplasms · China | 3 | Active, not recruiting | Dec 31, 2024 | 748 |
| NCT04827004Lymphoma, Large B-Cell, Diffuse · China | 2 | UNKNOWN | Dec 31, 2022 | 30 |
| NCT04809142Advanced Biliary Cancer · China | 3 | UNKNOWN | Mar 18, 2022 | 392 |
| NCT04439890Advanced Non-squamous Cell Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Jun 1, 2021 | 369 |
| NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China | 3 | UNKNOWN | Oct 31, 2023 | 528 |
| NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Active, not recruiting | Dec 2026 | 648 |
How it is read
Names in the registry
- “Anlotinib Hydrochloride Capsules”, 5 entries
- “Anlotinib hydrochloride capsule”, 4 entries
- “Anlotinib Hydrochloride Capsule”, 3 entries
- “Anlotinib Hydrochloride capsules”, 2 entries
- “Benmelstobart injection combined with Anlotinib hydrochloride capsule”, 1 entry
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 3 studies
- Carcinoma, Hepatocellular, 3 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Colorectal Neoplasms, 2 studies
- Sarcoma, Alveolar Soft Part, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.